Novavax COVID-19 vaccine shows 96% efficacy

Published by BBN Staff at March 15, 2021

Tags

Posted: Monday, March 15, 2021. 1:43 pm CST.

By Zoila Palma: Final data from the third phase of the Novavax COVID-19 vaccine study revealed that after evaluation, the vaccine was 96.4% effective against mild, moderate, and severe disease caused by the original COVID-19 strain in the United Kingdom.

In addition, Yahoo News reports that the company’s phase IIb study demonstrated that the vaccine candidate delivered 55.4% efficiency among the HIV-negative study participants.

The Novavax vaccine also showed 100% protection against severe disease and significantly reduced mild and moderate diseases across both the studies.

The company is now seeking to submit the data for authorization to several regulatory agencies worldwide.

The Novavax vaccine has also shown 86% efficacy against the new circulating variant, B.1.1.7/501Y.V1, in the United Kingdom.

Several other companies have launched vaccines for fighting COVID-19.

Advertise with the mоѕt vіѕіtеd nеwѕ ѕіtе іn Belize ~ We offer fully customizable and flexible digital marketing packages. Your content is delivered instantly to thousands of users in Belize and abroad! Contact us at mаrkеtіng@brеаkіngbеlіzеnеwѕ.соm or call us at 501-612-0315.